Glenmark Gets CDSCO Panel Nod to Study ISB 2001 in Multiple Myeloma Dr. Divya Colin28 Feb 2024 6:00 PM ISTNew Delhi: The drug major Glenmark has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
GSK gets CDSCO Panel Nod To study Anti-cancer Drug Belantamab mafodotin Dr. Divya Colin25 Feb 2024 6:00 PM ISTNew Delhi: The drug major GSK has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Obesity to Detect Blood Cancer Precursor Finds Study Niveditha Subramani13 Jan 2024 4:36 PM ISTObesity is not only a metabolic disease but has long been considered a major risk factor for cancer and is the only known modifiable risk factor...
Submit Separate Toxicity Data on Indian Subject: CDSCO Panel Tells GSK on BelantamabMafodotin study Dr. Divya Colin4 Jan 2024 6:00 PM ISTNew Delhi: Considering the serious adverse events in the study data (phase-I & II) of Belantamab Mafodotin (GSK2857916) for Injection 100mg...
CDSCO panel Approves Pfizer's Protocol Amendment Proposal for Anti-cancer Drug Elranatamab Dr. Divya Colin2 Jan 2024 5:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
AstraZeneca to buy Gracell Biotechnologies for USD 1.2 billion Ruchika Sharma27 Dec 2023 10:00 AM ISTCambridge: AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical...
Lower HDL-C, total cholesterol and apolipoprotein A-I levels encountered in multiple myeloma Medha Baranwal21 Dec 2023 11:30 PM ISTCyprus: A recent study published in Atherosclerosis Plus has reported a significant reduction in HDL-C, total cholesterol (TC), and apolipoprotein A-I...
Sarclisa plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone: Sanofi Ruchika Sharma11 Dec 2023 2:30 PM ISTParis: Sanofi has announced that the Phase 3 trial investigating Sarclisa (isatuximab) in combination with carfilzomib, lenalidomide and...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Pfizer Elrexfio gets European Commission approval for Multiple Myeloma Ruchika Sharma9 Dec 2023 12:00 PM ISTThe conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
GSK declares positive results from phase III trial for Blenrep in relapsed/ refractory multiple myeloma Ruchika Sharma28 Nov 2023 12:30 PM ISTLondon: GSK plc has announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial...
